Since the activation of T lymphocytes favors the generation of CLL cells that are less sensitive to venetoclax, the strong reduction in venetoclax resistance due to SPHK inhibitors (Figure 2A) might involve an effect on T cell activation and/or survival. Here, SPHK1 is linked to B-cell chronic lymphocytic leukemia.